- Oops!Something went wrong.Please try again later.
CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report fourth quarter and full-year 2018 financial results on Thursday, March 28, 2019, before market open.
The company will not be conducting a teleconference in conjunction with its financial results press release.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, or follow us on Twitter and LinkedIn.
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
+1 (973) 271-6085